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RetinaThe geographic origins of populations can be identiﬁed by their maternally inherited mitochondrial DNA
(mtDNA) haplogroups. This study compared human cybrids (cytoplasmic hybrids), which are cell lines with
identical nuclei but mitochondria from different individuals with mtDNA from either the H haplogroup or L
haplogroup backgrounds. The most common European haplogroup is H while individuals of maternal African
origin are of the L haplogroup. Despite lower mtDNA copy numbers, L cybrids had higher expression levels
for nine mtDNA-encoded respiratory complex genes, decreased ATP (adenosine triphosphate) turnover rates
and lower levels of reactive oxygen species production, parameters which are consistent with more efﬁcient ox-
idative phosphorylation. Surprisingly, GeneChip arrays showed that the L and H cybrids hadmajor differences in
expression of genes of the canonical complement system (5genes), dermatan/chondroitin sulfate biosynthesis (5
genes) and CCR3 (chemokine, CC motif, receptor 3) signaling (9 genes). Quantitative nuclear gene expression
studies conﬁrmed that L cybrids had (a) lower expression levels of complement pathway and innate immunity
genes and (b) increased levels of inﬂammation-related signaling genes, which are critical in human diseases.
Our data support the hypothesis that mtDNA haplogroups representing populations from different geographic
origins may play a role in differential susceptibilities to diseases.
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Mitochondria (mt) have their own unique, circular DNA that can be
categorized into haplogroups deﬁned by single nucleotide polymor-
phism (SNP) variants, and these haplogroups represent populations of
different ancestral origin. Recent studies have shown that mtDNA
haplogroups can be associated with human aging and diseases [1]. The
coding region of mtDNA encodes for 37 genes including 13 protein
subunits that are essential for oxidative phosphorylation (OXPHOS), 2
ribosomal RNAs and 22 transfer RNAs [2–4]. The non-coding mtDNA
D-loop (also called the Control Region) contains 1121 nucleotides and
is important for replication and transcription. It is known that mtDNA
is critical for OXPHOS but recent studies have provided evidence that
mtDNA haplogroups can also inﬂuence expression of genes related to
oxidative stress [5,6] and the clinical severity of diseases [7,8]. Most
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Fig. 1. a and b. Diagrams of haplogroups trees showing the subsets of L cybrids and H
cybrids used in this study. The mtDNA from the individual L cybrids were analyzed and
the SNPs which deﬁne the Loa1′4, L1b, and L2b haplogroup subsets are listed. The SNPs
listed were all veriﬁed by sequencing and comparison to the H haplogroup represents
the Cambridge reference standard used to deﬁne the mtDNA sequences.
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diseases, including Alzheimer's disease (AD) [9], Parkinson's disease
[10–12], osteoarthritis [13], type 2 diabetes (T2D) [14] and various
cancers [15].
In medicine, it has long been recognized that certain diseases are
more prevalent in speciﬁc racial/ethnic populations [16–21]. For
example, there are differences in the prevalence of Alzheimer's disease
(AD) depending upon the ethnic/racial groups. Proportionately to the
size of their population, older African-Americans are ~2-times more
likely and Hispanics are approximately 1.5-times more likely to have
AD or dementia compared to older non-Hispanic whites [22–24].
Another example of racial/ethnic differences can be found in the
incidence of diabetes. Compared to non-Hispanic white adults, Asian-
Americans have an 18% rate, Hispanic/Latinos have 66%, and non-
Hispanic blacks a 77% higher risk of diabetes (http://www.diabetes.
niddk.nih.gov/dm/pubs/statistics). With systemic lupus erythematosus
(SLE), there is higher incidencewithin the African-American community
compared to white subjects [20,21]. While some have suggested that
epigenetic changes may contribute to these ethnic/racial differences
[25], we suspect that non-synonymous mtDNA variants (causing
amino acid changes) associated with the different haplogroups may
contribute to altered functions and disease susceptibilities. In addition,
the SNP variants within the mt-D-loop region can cause changes in
replication and transcription rates, leading to lower levels of mtDNA
and mtRNA [26].
In the past it has been difﬁcult to evaluate the contribution that
mtDNA variants might have tomolecular processes or cellular behavior.
However, with the development and use of the novel cybrid (cytoplas-
mic hybrid)model,many questions related to the functional importance
of the mtDNA haplogroup variants and mitochondrial–nuclear interac-
tions can be addressed. These cybrid cell lines are created by fusing
mitochondrial-free (Rho0) cells with mitochondria-rich platelets from
different individuals so the resultant cells have identical nuclei but
vary in their mtDNA haplogroups.
Our initial interests have been related to age-related macular
degeneration andother retinal diseases, sowe elected to use awell char-
acterized retinal pigment epithelial cell line, ARPE-19, for our cybrids.
Our ﬁndings with this novel cybrid model show that surprisingly the L
haplogroup mtDNA variants (African origins) can differentially mediate
the expression of nuclear genes involved in the complement, inﬂamma-
tory and innate immunity pathways, which are critical in human
diseases. These data also support the hypothesis that the differential
susceptibilities to diseases found in ethnic/racial populations may be
related in part to their mtDNA haplogroup backgrounds, which can
inﬂuence nuclear gene expression, cellular functions and induce vari-
able phenotypic severity of diseases.
2. Material and methods
2.1. Transmitochondrial cybrids and culture conditions
Institutional reviewboard approvalwas obtained from theUniversity
of California, Irvine (#2003-3131). For DNA analyses, 10 ml of peripheral
blood was collected via venipuncture in tubes containing 3.2% sodium
citrate from normal volunteers (H haplogroup, n = 3, average age
35.3 ±7.3 years; L haplogroup, n = 3, average age 44.6 ± 4.8 years,
p =0.5). DNA was isolated with a DNA extraction kit (PUREGENE,
Qiagen, Valencia, CA). Plateletswere isolated by a series of centrifugation
steps and ﬁnal pellets were suspended in Tris-buffered saline. The ARPE-
19 cells deﬁcient inmtDNA (Rho0) were created by serial passage in low
dose ethidium bromide [27]. Cybrids were produced by polyethylene
glycol fusion of platelets with Rho0 ARPE-19 cells according to modiﬁed
procedures of Chomyn [28]. Veriﬁcation of transfer of the mitochondria
into the Rho0 ARPE-19 cells was accomplished by polymerase chain
reaction (PCR), restriction enzyme digestion, and sequencing of the
mtDNA to identify the mitochondrial haplogroup of each cybrid [29].2.2. Identiﬁcation of cybrid haplogroups
Cybrid DNA was extracted from cell pellets using a spin column kit
(DNeasy Blood and Tissue Kit, Qiagen) and quantiﬁed using the
Nanodrop 1000 (ThermoScientiﬁc,Wilmington,DE). PCR and restriction
enzyme digests [29] allelic discrimination and sequencing of the mt-
Dloop were performed to determine mitochondrial haplogroups. The H
deﬁning SNPs were T7028C, G73A, G2706A, A11719G and T14766C.
The samples were further sequenced and identiﬁed to be H, H and H5a
for the three cybrids (Fig. 1a). The L cybrids were further sequenced
using primers to L9611-H12111 and to the mt-Dloop. The L samples
were identiﬁed to be L0a1′4, L1b, and L2b as deﬁned by the SNP variants
(Fig. 1b).
Allelic discriminationwas also performed to conﬁrm thehaplogroups.
The primers for allelic discrimination were synthesized by ABI Assay-by-
Design. The samples were run at GenoSeq, the UCLA Genotyping and
Sequencing Core, on an ABI 7900HT. Data were analyzed with Sequence
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cybrid cells for the assays described below.
2.3. ROS production
Cybrids from different individuals with either H (n = 3) or L
(n = 3) haplogroups were incubated in 24 well plates (1 ×105 -
cells/well). After 24 h, the cells were exposed to ﬂuorescent dye, 2′,7′-
dichlorodihydroﬂuorescein diacetate (H2DCFDA, Invitrogen-Molecular
Probes) and ROS production wasmeasured by the FMBio III instrument
at 490 nM. The values represent results combined from different
cybrids with H (n = 3) or L (n = 3) haplogroups, each experiment
was repeated two times, and the assays run in quadruplicate.
For comparison, cybrids containing J haplogroups (n = 3) were also
analyzed for ROS production levels.
2.4. ATP production assay
Intracellular ATP levels were measured for H and L cybrids using the
luminescence ATP detection assay (ATPlite Perkin Elmer Inc., Waltham,
MA USA) as per the supplier's instructions. Cybrid lines (H cybrids
n = 3, L cybrids n = 3) were cultured 24 h on a 96 well plate at 2
different concentrations, 100 K and 50 K cells per well with a ﬁnal
volume of 100 μl/well. Luminescence was measured using a Synergy
HT Multi-Mode microplate reader and Gen5 Data Analysis software
(BioTek instruments,Winooski, VTUSA). All experimentswere repeated
twice and assayed in quadruplicate.
2.5. Lactate assay
Lactate concentrations in the H (n = 3) and L (n = 3) cybrid
samples were measured by the Lactate Assay Kit (Eton Bioscience Inc.,
San Diego, CA). Cells were plated at 100 K and 50 K in 96-well plates
and incubated overnight. Lactate levels were measured according to
the manufacturer's protocol. Standards and samples were set up as
duplicates and quadruplicates and experiments were repeated twice.
2.6. Growth curve assay
The growth curves of three different H cybrids were compared to
three different L cybrids over six days, under similar environmental
conditions. The different H cybrids and L cybrids were grown to passage
5 using methods described above. 300,000 cells per well were plated
onto six-well plates, incubated in standard conditions and culture
medium was changed every other day. The cell numbers were mea-
sured using a Cell Viability Analyzer (ViCell, Beckman Coulter, Miami,
FL). The numbers of cells plated at time-point 0 were designated as
100% and the percentage increase in growth for each cybrid at Days 2,
4, and 6 were calculated. A mean percentage increase value of all
threeH cybrids and three L cybridswere compared by nonlinear regres-
sion analysis (Prism, version 5.0; GraphPad Software Inc., San Diego,
CA). Within each experiment the assays were run in duplicate and the
experiments repeated twice.
2.7. Extracellular ﬂux analysis
The oxygen consumption rate (OCR) and bioenergetic proﬁles for
the cybrids were measured at 37 °C using a Seahorse XF Extracellular
Flux Analyzer (Seahorse Bioscience, Billerica, MA). Cybrids with
haplogroups H (n = 3) and L (n = 3) were plated at 30,000 cells/well
and cultured overnight at 37 °C under 5% CO2. Sampleswere run in trip-
licate and experiments repeated three times. Plates were then washed
and placed 1 h in a 37 °C incubator under air in 500 μl of unbuffered
DMEM (Dulbecco's modiﬁed Eagle's medium, pH 7.4), supplemented
with 17.5 mM glucose (Sigma, St Louis, MO), 200 mM L-glutamine
(Invitrogen-Molecular Probes, Carlsbad, CA) and 10 mM sodiumpyruvate (Invitrogen-Molecular Probes). There was sequential injection
into the wells of Oligomycin (1 μM ﬁnal concentration, which blocks
ATP synthase to assess respiration required for ATP turnover), FCCP
(1 μM ﬁnal concentration, a proton ionophore which induces chemical
uncoupling and maximal respiration), and Rotenone plus Antimycin A
(1 μMﬁnal concentration of each, completely inhibits electron transport
to measure non-mitochondrial respiration). Data from each well were
normalized by measuring total protein. Total protein was isolated with
Ripa lysis buffer (Millipore, Billerica, MA) containing protease inhibitor
(Sigma, St. Louis, MO) and phosphatase arrest (Gbiosciences, St. Louis,
MO). Isolated protein was mixed with Qubit buffer and measured with
Qubit 2.0 ﬂuorometer (Invitrogen, Grand Island, NY).
All data from XF24 assays were collected using the XF Reader soft-
ware from Seahorse Bioscience. The OCR is determined by measuring
the drop in O2 partial pressure over time followed by linear regression
to ﬁnd the slope. The ECAR is determined by measuring the change in
pH levels over time followed by linear regression to ﬁnd the slope of
the line which represents ECAR. The percentage ATP Turnover Rate is
calculated by the following formula: 100 − (ATP coupler response/
basal respiration × 100). The percentage Spare Respiratory Capacity
represents a bioenergetic value for cells needing high amounts of ATP
in response to demands placed upon them. This is calculated by the
formula: electron transport chain (ETC) accelerator response/basal
respiration × 100. The percentage Proton Leak equals the ATP coupler
response — non-mitochondrial respiration. Data from these experi-
ments were exported to GraphPad Prism 5 (GraphPad Software, La
Jolla, CA, USA) where they were analyzed, normalized and graphed.
Statistical signiﬁcance was determined by performing two-tailed Stu-
dent t tests and p ≤ 0.05 was considered signiﬁcant in all experiments.
2.8. Isolation of RNA and ampliﬁcation of cDNA
Cells from cybrid cultures (H cybrids, n = 3 and L cybrids, n = 3)
were pelleted, and RNA isolated using the RNeasy Mini-Extraction kit
(Qiagen, Inc.) following the manufacturer's protocol. The RNA was
quantiﬁed using a NanoDrop1000 (ThermoScientiﬁc). For Q-PCR analy-
ses, 100 ng of individual RNA samples were reverse transcribed into
cDNA using the QuantiTect Reverse Transcription Kit (Qiagen).
2.9. Gene expression arrays and statistical analyses
For the GeneChip array analyses, equal amounts of RNAs (250 ng/μl
per sample) from H cybrids (n = 3) were combined into a single sam-
ple. This was compared to the sample of combined RNAs from L cybrids
(250 ng/μl per sample, n = 3). The RNA samples were sent to the UCLA
Clinical MicroArray Core Lab for analyses with the Affymetrix Human
U133 Plus 2.0 Array. Gene expression results were analyzed with IPA
summary pathway analysis software (INGENUITY Systems, Redwood
City, CA). The array analyses showed that genes related to inﬂammation,
complement activation and cell signaling pathways were differentially
expressed in the H versus the L cybrids. The raw and processed data
ﬁles can be accessed through NCBI Gene Expression Omnibus (GEO)
Series.
2.10. Quantitative PCR (Q-PCR) analyses
Gene expression changes identiﬁed by the GeneCHip array were
veriﬁed by Q-PCR using 19 different primers (QuantiTect Primer
Assay, Qiagen) for genes associated with complement pathway (CFH,
CFHR4, CFP, CFP-var1, CD55/DAF, C3, CD59, C1QC, C1S, C1R, C4B, and
C4BPB) and inﬂammatory genes (TGFA, TGFB2, IL-33, IL-6, NFκB2,
MAPK8, and MAPK10). In addition, twelve mtDNA-encoded genes
were also analyzed by Q-PCR using primers obtained from Drs. Marquis
Vawter and Nitin Udar (Integrated DNA Technologies, Inc., Coralville,
IA). The Q-PCR analyses were performed on individual H or L cybrids
and not on combined samples. Total RNA was isolated from individual
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haplogroup L cybrids (n = 3) as described above. These cDNA samples
were not pooled but rather analyzed individually. Q-PCR was
performed on individual samples using a QuantiFast SYBR Green PCR
Kit (Qiagen) on a Bio-Rad iCycleriQ 500 detection system and expres-
sion levels were standardized for all primers using TATA box binding
protein (TBP) as the reference gene. The C1QC, C1S, and C4BPB primers
were runwith the housekeeping geneHMBS. The C4B primerswere run
with the housekeeping geneHPRT1. All otherswere runwith the house-
keeping gene TBP. The analyses were performed in triplicate. Statistical
analyses of gene expression levels were performed to measure
difference between haplogroups using Prism, version 5.0; (GraphPad
Software Inc.).
2.11. Statistical analyses
Data were subjected to statistical analysis by ANOVA and GraphPad
Prism (version 5.0). Newman–Keuls multiple-comparison test was
done to compare the data within each experiment. p b 0.05 (two-
sided) was considered statistically signiﬁcant. Error bars in the graphs
represent SEM (standard error mean).
3. Results
For the following series of experiments there were three H cybrids
from different individuals (subsets H, H and H5a) and three L cybrids
from different individuals (subsets L0a1′4, L1b and L2b). In the various
assays, all samples were analyzed independently except for the
Affymetrix GeneChip experiment, which had equal amounts of RNA
from the three H cybrids or the three L cybrids combined for the
assay. However, based upon the GeneChip results, we ran Q-PCR forFig. 2. a) H and L cybrids that were plated at 100 K cells or 50 K cells per well showed similar
assayed in quadruplicate. b) The lactate production levels were similar in the H and L cybrids
All experiments were repeated twice and assayed in quadruplicate. c) After being cultured 2
(**p b 0.01) and the L cybrids (*p b 0.05). d) At Day 0, 300 K cells per well were plated and t
at a similar growth rate pattern to the H cybrids. ROS/RNS reactive oxygen/nitrogen species; Cspeciﬁc genes with individual RNA samples from each of the different
cybrids.
3.1. ROS, ATP and lactate production levels and growth curve analysis
The ATP and lactate levels were similar in the H (n = 3) and L
(n = 3) cybrid cultures (Fig. 2a and b). We compared the H and L
cybrids plated at concentrations of 100 K cells or 50 K cells per well
for the relative ATP and lactate levels. The ATP production levels were
similar in the H cybrids compared to the L cybrids in the cultures with
100 K cells (100% versus 98.86 ± 0.75, p = 0.27) and 50 K cells
(94.13 ± 10.72 versus 77.24 ± 5.10, p = 0.4). Lactate levels were
similar in the H cybrids and L cybrids in the 100 K/well cultures
(99.95 ± 0.05 versus 95.6 ± 1.9, p = 0.22) and 50 K/well cultures,
(73.3 ± 12.0 versus 71.2 ± 8.8, p = 0.89).
The ROS production for the L cybrids was signiﬁcantly lower than
the H cybrids (Fig. 2c). As oxygen consumption occurs, electron leakage
from the electron transport chain (ETC) can cause increased production
of endogenous ROS. The L cybrids (74.21% ± 6.21%, p = 0.007) had
lower ROS production levels compared to the H cybrids (99.5% ±
0.29) which was unexpected because of the production levels of ATP
were similar in the H and L cybrid cultures. In order to verify the ROS
assay, we also measured the ROS production of J cybrids, which are
known to have lower levels than H cybrids [30]. We found that
J-cybrid ROS levels were signiﬁcantly lower than the H cybrids
(83.46% ± 1.84%, p = 0.006) but were not signiﬁcantly different from
the L cybrids (p = 0.13).
Since the J cybrids have been shown to have a higher growth rate
than H cybrids [30] we wanted to compare the growth rates of the L
cybrids and H cybrids over a six day incubation period (Fig. 2d). The L
and H cybrids had similar slopes to their growth rate curves at all timelevels of ATP production after 24 h incubation. All experiments were repeated twice and
when plated at concentrations of 100 K cells and 50 K cells per well and cultured 24 h.
4 h, the H cybrids showed increased production levels of ROS compared to the J cybrids
he cell viabilities measured at Days 2, 4, and 6. The graph shows that the L cybrids grew
ybd, cybrid.
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Day 4, 159% versus 178%, Day 6, 256% versus 279%).3.2. Measurements of the bioenergetic proﬁles for cybrids
The bioenergetic proﬁles in the H (n = 3) and L (n = 3) cybrids
were measured after sequential treatments with Oligomycin, FCCP
and Rotenone/Antimycin A using values generated by the Seahorse
XF24 ﬂux analyzer. Fig. 3a shows the proﬁle representing basal respira-
tion, ATP turnover, maximal respiration, spare respiratory capacity,
proton leak and non-mitochondrial respiration. The percentage ATP
turnover rate was signiﬁcantly higher for the H cybrids compared to
the L cybrids (49.42 ± 1.3 versus 41.3 ± 3.1, p = 0.024, Fig. 3b). The
percentage spare respiratory capacity of the H cybrids (166.5 ± 4.07)
was signiﬁcantly higher than the L cybrids (143.4 ± 4.7, p = 0.02,
Fig. 3c). The percentage proton leak values for the H cybrids (12.43 ±
1.27) were similar to the L cybrids (15.13 ± 0.8, p = 0.09).
The Seahorse XF24 ﬂux analyzer allows for real-time measurement
in the individual wells of the oxygen consumption rates (OCR)
representing the basal aerobic respiration of the cells and extracellularFig. 3. a) Schematic representation showing regions that deﬁne the basal aerobic respiratio
mitochondrial respiration as measured by Seahorse XF24 ﬂux analyzer. b) In response to Oli
the H cybrids (*p = 0.05). c) After treatment with Antimycin A plus Rotenone, the L cyb
(*p = 0.05). d) The percentage proton leak levels were similar in the H and L cybrids (p = 0.0acidiﬁcation rates (ECAR) representing glycolysis. The OCR to ECAR ra-
tios for the H and L cybrids were not signiﬁcantly different from each
other (23.85 ± 2.50 versus 17.17 ± 2.44, p = 0.1).3.3. Levels of expression for mtDNA encoded genes
The H and L haplogroups are deﬁned by speciﬁc patterns of SNPs,
some of which are non-synonymous SNPs that lead to amino acid
changes within the OXPHOS respiratory complexes. Using the cybrid
model (H cybrids, n = 3 and L cybrids, n = 3), we measured the
expression levels of themtDNA encoded genes in respiratory complexes
I, III, IV, and V of the OXPHOS pathway and normalized the H cybrids
values to 1 (Table 1). The L cybrids showed signiﬁcantly higher gene
expression levels of nine of the genes compared to H cybrids: Complex
I, mt-ND1 (p = 0.047), mt-ND4/ND4L (p = 0.005), mt-ND5 (p =
0.007); mt-ND6 (p = 0.019); Complex III, mt-CYB (p = 0.006);
Complex IV, (mt-CO1 (p = 0.004), mt-CO2 (p = 0.033), mt-CO3
(p = 0.025); Complex V, mt-ATP6 (p = 0.015); and mt-ATP8
(p = 0.013). Only the mt-ND4/ND4L expression levels in the L cybrids
were lower than the H cybrids (p = 0.005).n, ATP turnover, maximal respiration, spare respiratory capacity, proton leak and non-
gomycin treatment, the L cybrids showed signiﬁcantly lower ATP turnover compared to
rids showed signiﬁcantly lower spare respiratory capacity compared to the H cybrids
9). Cybd, cybrid.
Table 1
Q-PCR expression levels formtDNA encoded genes from complexes I, III, IV, and V found in
the L versus H cybrids.
Symbol Gene name L vs. H L vs. H
p-value ΔΔCT/fold
MT-ND1 NADH dehydrogenase subunit 1 0.047 0.65 ± 0.30/1.57
MT-ND2 NADH dehydrogenase subunit 2 0.338 0.37 ± 0.37/1.29
MT-ND3 NADH dehydrogenase subunit 3 0.337 0.40 ± 0.41/1.32
MT-ND4/ND4L NADH dehydrogenase subunit 4/4L 0.005 −2.64 ± 0.81/0.16
MT-ND5 NADH dehydrogenase subunit 5 0.007 1.07 ± 0.34/2.10
MT-ND6 NADH dehydrogenase subunit 6 0.019 0.90 ± 0.35/1.87
MT-CYB Cytochrome b 0.006 1.08 ± 0.34/2.11
MT-CO1 Cytochrome c oxidase subunit I 0.004 0.95 ± 0.29/1.93
MT-CO2 Cytochrome c oxidase subunit II 0.033 0.83 ± 0.36/1.78
MT-CO3 Cytochrome c oxidase subunit III 0.025 0.79 ± 0.32/1.73
MT-ATP6 ATP synthase F0 subunit 6 0.015 0.85 ± 0.31/1.80
MT-ATP8 ATP synthase F0 subunit 8 0.013 0.86 ± 0.31/1.82
N = 3 with six values for each sample.
Fold values greater than 1 indicate up regulation of the gene compared to H cybrids. H
cybrids are assigned a value of 1.
Fold values less than 1 indicate down regulation of the gene compared to H cybrids. H
cybrids are assigned a value of 1.
Fold = 2−ΔΔCT.
213M.C. Kenney et al. / Biochimica et Biophysica Acta 1842 (2014) 208–2193.4. Levels of expression of nuclear genes related to complement activation,
inﬂammation and apoptosis
Based upon differences in the expression of mtDNA-encoded
OXPHOS complexes found in H and L cybrids, we hypothesized that
the cybrids might also have different gene expression patterns for
other pathways. Therefore, we isolated the RNA of three H cybrids and
three L cybrids, pooled equal quantities from each sample and then
analyzed them using the GeneChip array that characterizes gene
expression for over 40 K genes. These data were then analyzed with
the Ingenuity software program which showed that the pooled RNA
from the L cybrids had statistically signiﬁcant differences in the
Complement System, CCR3 Signaling in Eosinophils, Dermatan Sulfate
Biosynthesis (late stages), and Chondroitin Sulfate Biosynthesis (late
stages) compared to the pooled RNA from the H cybrids (Tables 2a
and 2b). We were surprised that differences in major pathways of
nuclear genes unrelated to energy production were found in these
cybrids with the identical nuclei, cytoplasm and culture conditions but
varying only in the haplotype of their mitochondria.
The signiﬁcance of our Affymetrix gene array studies is that by IPA
analyses, the four pathways with the greatest changes are related to
complement activation, inﬂammation and autoimmunity. This strongly
suggests that mtDNA can greatly inﬂuence the expression of nuclear
gene pathways associated with diseases which are more prevalent in
African populations (e.g., SLE, diabetes, asthma). The next series of
experiments were to verify the genes of the complement pathway but
in the future we will need to perform Q-PCR to measure expression
levels for the CCR3 and sulfotransferase pathways.
We used Q-PCR to analyze twelve nuclear genes associated with the
complement pathway and seven nuclear genes related to cell signaling
and inﬂammation (Table 3). In the Q-PCR studies, we analyzed the RNA
from individual cybrids (H haplogroups, n = 3 and L haplogroups,Table 2a
Comparison of gene expression differences in canonical pathways for L cybrids versus H cybri
Array.
Ingenuity canonical pathways p-value Ratio
Complement system 0.00298 5/35 (0.143)
CCR3 signaling in eosinophils 0.00688 9/126 (0.071)
Dermatan sulfate biosynthesis (late stages) 0.00794 5/47 (0.106)
Chondroitin sulfate biosynthesis (late stages) 0.00975 5/54 (0.093)n = 3). We demonstrated that the L cybrids showed decreased levels
for C1QC (0.46 fold, p = 0.0002), C1R (0.16 fold, p = 0.025), C3 (0.17
fold, p = 0.0004), and CFH (0.58 fold, p = 0.009) compared to H
cybrids. There was a trend for decreased values for the C1S gene but
it did not quite reach signiﬁcance (0.21 fold, p = 0.063). The
inﬂammation-related (type 2 immunity) genes, TGFA and IL-33, were
expressed at lower levels in the L cybrids (0.4 fold, p = 0.02 and 0.3
fold, p = 0.002) compared to the H cybrids. The L cybrids had higher
expression levels for NFκB2 (1.36 fold, p = 0.0013) and MAPK10
(1.62 fold, p = 0.004). TheH and L cybrids had similar expression levels
of the IL-6, TGFB2, and MAPK8 genes.
3.5. mtDNA copy numbers
The mtDNA copy numbers in the H and L cybrid cultures were mea-
sured by Q-PCR using 18S to represent nDNA and mt-ND2 to represent
mtDNA. An average of 3 independent representatives was used for each
haplogroup and run in triplicate. At Day 1, the L cybrids had nDNA:
mtDNA ratios of 1.26 ± 0.007 (p b 0.0001) and at Day 7, the ratio
was 1.18 ± 0.06 (p b 0.036), which were signiﬁcantly lower than the
H haplogroup cybrids (H cybrids at Day 1 were 1.38 ± 0.016 and day
7 were 1.31 ± 0.022). Therefore, our results showed that the L
haplogroup cybrids had decreased mtDNA copy numbers compared to
the H cybrids.
4. Discussion
Over the past few decades, there have been tremendous advances
in the identiﬁcation of nuclear genes that are associated with human
diseases but there are still many questions with respect to population
susceptibilities to diseases. We hypothesize that mtDNA variants
contribute to this susceptibility for the following reasons: 1) Single
mtDNA mutations can have profound effects on tissues and lead to
debilitating and lethal diseases [1]. Within the mtDNA haplogroups,
there are large accumulations of SNPs that have occurred over thou-
sands of years, some of which cause amino acid and functional changes,
while others cause changes in the rates of replication and transcription
of themtDNA. These SNP variations can inﬂuence levels of ATP and ROS,
which are signaling elements for pathways that can affect cellular
behavior. 2) Our laboratory, along with others, have used the cybrid
model to provide evidence that mtDNA haplogroups can mediate
expression of nuclear genes, rates of cell growth and cell behavior
[5,6,30]. In addition, clinical studies have shown that mtDNA
haplogroups can inﬂuence the severity and penetrance of diseases
[7,8]. It is reasonable to speculate that if an ethnic/racial population
has a mtDNA haplogroup proﬁle which causes major alterations in
gene expression within a disease-related pathway (i.e. complement or
innate immunity), that this group may respond uniquely to nuclear ge-
netic patterns or environmental patterns compared to a population
with a totally different mtDNA haplogroup SNP proﬁle (Fig. 4). In
other words, we propose that when we look at diseases, we not only
examine the nuclear genetics and environmental factors, but also
include the mtDNA haplogroup backgrounds because the mtDNA pro-
ﬁles, as indicated by our model system, seem to greatly inﬂuence the
nuclear genes expressed for major pathways related to diseases.ds as determined by IPA summary program analyses of Affymetrix Human U133 Plus 2.0
Molecules
C1R, CFD, C3, C1S, CFH
GNAI3, PLA2G4A, GNB4, MPRIP, PIK3C2A, PLA2G4C, GNB1L, PRKD3, LIMK1
CHST2, CHST5, SULT1C2, HS3ST1, CHST15
CHST2, CHST5, SULT1C2, HS3ST1, CHST15
Table 2b
Details of the genes most differentially expressed in the canonical pathways as identiﬁed by the Affymetrix Human U133 Plus 2.0 Array (see Table 2a).
Probe set ID Representative
public ID
Gene title Gene
symbol
CYBD-L
signal
CYBD-H
signal
L vs H
(fold)
Complement pathway
205382_s_at NM_001928 Complement factor D (adipsin) CFD 110.2228 221.9749 −2.014
217767_at NM_000064 Complement component 3 C3 47.80712 266.4335 −5.573
208747_s_at M18767 Complement component 1, s subcomponent C1S 373.5514 1077.674 −2.885
213800_at X04697 Complement factor H CFH 374.2268 731.5613 −1.955
233645_s_at AK024084 Complement component 1, r subcomponent-like C1RL 34.92233 80.27631 −2.299
212067_s_at AL573058 Complement component 1, r subcomponent C1R 462.3373 921.95 −1.994
CCR3 signaling in eosinophils
201179_s_at J03005 Guanine nucleotide binding protein (G protein),
alpha inhibiting activity
polypeptide 3
GNAI3 1984.761 964.717 2.057
210145_at M68874 Phospholipase A2, group IVA (cytosolic, calcium-
dependent)
PLA2G4A 508.0608 239.0316 2.125
225710_at H99792 Guanine nucleotide binding protein (G protein), beta
polypeptide 4
GNB4 2083.321 1604.451 1.298
This gene is on 2 lines but it should be on a single line
similar to the other genes. 238330_s_at
BE545235 Myosin phosphatase Rho The Gene Title should be
"Myosin phosphatase Rho interacting protein" and
then the rest of the information should follow in the
same row.
Interacting protein The "interacting protein" should be
in the Gene Title box and the rest of the information
should follow in the same row.
Myosin
phosphatase
Rho interacting
protein
45.4356 38.30487 1.186
213070_at AV682436 Phosphoinositide-3-kinase, class 2, alpha
polypeptide
PIK3C2A 3398.176 3108.479 1.093
1554810_at BC017956 Phospholipase A2, group IVC (cytosolic, calcium-
independent)
PLA2G4C 2.814504 3.745029 −1.331
204357_s_at NM_002314 LIM domain kinase 1 LIMK1 364.5368 172.3025 2.116
Dermatan sulfate biosynthesis (late stages)
203921_at NM_004267 Carbohydrate (N-acetylglucosamine-6-O)
sulfotransferase 2
CHST2 172.4877 574.8635 −3.333
221164_x_at NM_012126 Carbohydrate (N-acetylglucosamine 6-O)
sulfotransferase 5
CHST5 166.9994 66.77411 2.501
205342_s_at AF026303 Sulfotransferase family, cytosolic, 1C, member 2 SULT1C2 1550.949 727.0483 2.133
213991_s_at BF940710 Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 HS3ST1 8.171075 11.56858 −1.416
203066_at NM_014863 Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O)
sulfotransferase 15
CHST15 123.3805 259.3976 −2.102
Chondroitin sulfate biosynthesis (late stages)
203921_at NM_004267 Carbohydrate (N-acetylglucosamine-6-O)
sulfotransferase 2
CHST2 172.4877 574.8635 −3.333
221164_x_at NM_012126 Carbohydrate (N-acetylglucosamine 6-O)
sulfotransferase 5
CHST5 166.9994 66.77411 2.501
This gene is on2 lines but should be on a single line. The
Gene title should be "sulfotransferase family,
cytosolic, 1C, member 2". Then the rest of the should
be on that single line.205342_s_at
AF026303 Sulfotransferase family, cytosolic, 1C,
Member 2 the "member 2" should be in the Gene Title
box and the rest of the row should follow.
sulrotransferase
family,
cytocolic, 1C,
member 2
1550.949 727.0483 2.133
213991_s_at BF940710 Heparan sulfate (glucosamine) 3-O-sulfotransferase
1
HS3ST1 8.171075 11.56858 −1.416
203066_at NM_014863 Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O)
sulfotransferase 15
CHST15 123.3805 259.3976 −2.102
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lactate and growth curve assays for each L-subtype and H-subtype.
We found that within the L-subtypes, the values trended together
while the H values were similar to each other. In other words, there
was not a particular subtype, either H or L, that stood out from the
others and this is reﬂected in that the error bars were relatively low
and that there were no differences in the ATP, lactate and growth
curve assays. In addition, based upon the information presently at
hand, it was not possible to assign the differences found in the gene ex-
pression levels to individual SNPs. However, when additional cybrids
are generated, we should be able to analyze the data with programs tohelp us understand the potential consequences of the particular mito-
chondrial variants.
4.1. Respiration rates andmtDNA encoded genes for complexes I, III, IV, and V
The XF24 Flux analyzer allows for simultaneous, real-timemeasure-
ments of bioenergetic proﬁles for multiple cybrid samples. In our study,
measurements were taken after different compounds were added
sequentially to metabolically alter the bioenergetic proﬁle of the
cybrids. Oligomycin acts as an ATP coupler which inhibits ATP synthase
(Complex V). FCCP, an ETC accelerator, acts as an uncoupling agent as it
Table 3
Q-PCR analyses for differential gene expressions found in the L versus H cybrids. The accession no. for C1R is not correct . Omit NM_0000186 and replace with NM_001733 and
NM_001124624. Also it should be complement component 1, r subcomponent and NOT factor H.. I tried to make the changes in the table but was not able to.
Symbol Gene name GenBank accession no. L vs. H p-value L vs. H ΔΔCT/fold Pathways/functions
C1QCa Complement component 1, q subcomponent, C chain NM_001114101
NM_172369
0.0002 −1.13 ± 0.23/0.46 Classical complement
C1Sa Complement component 1, s subcomponent NM_001734
NM_201442
0.063 −2.28 ± 1.14/0.21 "
C1Ra Complement component 1, r subcomponent NM_000186 0.025 −2.65 ± 1.07/0.16 "
C4Bb Complement component 4B (Chido blood group) NM_001002029
NM_000592
0.35 −0.89 ± 0.39/0.54 "
C4BPBa Complement component 4 binding protein, beta NM_000716
NM_001017364
NM_001017365
NM_001017366
NM_001017367
0.06 −1.19 ± 0.57/0.44 "
CFHR4 Complement factor H-related 4 NM_006684
NM_001201550
NM_001201551
0.09 −0.84 ± 0.46/0.56 "
C3 Complement component 3 NM_000064 0.0004 −2.6 ± 0.6/0.17 Classical and Alternative
CFH Complement factor H NM_000186 0.009 −0.8 ± 0.3/0.58 Alternative Complement
CFPa Complement factor properdin NM_001145252
NM_002621
0.1 −0.38 ± 0.22/0.77 "
CFP- var 1a Complement factor properdin NM_002621 0.52 −0.51 ± 0.77 "
CD59 CD59 molecule, complement regulatory protein NM_000611
NM_203329
NM_203331
NM_001127223
NM_001127225
NM_00112722
NM_001127227
0.17 0.19 ± 0.13/1.14
CD55/DAF Decay accelerating factor for complement NM_000574
NM_001114543
NM_001114544
NM_001114752
0.14 −0.37 ± 0.24/0.77 "
TGFA Transforming growth factor, alpha NM_003236
NM_001099691
0.02 −1.31 ± 0.53/0.40 Activates signaling pathway
for cell proliferation, differentiation
TGFB2 Transforming growth factor, beta 2 NM_003238
NM_001135599
0.27 −0.28 ± 0.25/0.82 Regulates proliferation,
differentiation, adhesion, migration
IL-33 Interleukin 33 NM_033439
NM_001199640
NM_001127180
0.002 −1.74 ± 0.46/0.30 Proinﬂammatory, Involved in production
of T helper cytokines
IL-6 Interleukin 6 NM_000600 0.11 −1.37 ± 0.81/0.39 Involved in inﬂammation and
maturation of B cells.
NFKB2 Nuclear factor of kappa light polypeptide gene
enhancer in B-cells 2
NM_001077494
NM_001077493
NM_002502
0.0013 0.44 ± 0.13/1.36 Central activator of inﬂammation
and immune function genes
MAPK8 Mitogen-activated protein kinase 8 NM_139046
NM_002750
NM_139047
NM_139049
0.7 −0.08 ± 0.21/0.95 Targets speciﬁc transcription factors
involved with apoptosis
MAPK10 Mitogen-activated protein kinase 10/JNK3 NM_002753
NM_138980
NM_138982
0.004 0.7 ± 0.21/1.62 Regulatory role in signaling pathways
during apoptosis
N = 3 with six values for each sample.
Fold values greater than 1 indicate up regulation of the gene compared to H cybrids. H cybrids are assigned a value of 1.
Fold values less than 1 indicate down regulation of the gene compared to H cybrids. H cybrids are assigned a value of 1.
Fold = 2−ΔΔCT.
a These primers were run with the housekeeping gene HMBS.
b These primers were run with the housekeeping gene HPRT1. All others were run with the housekeeping gene TBP.
215M.C. Kenney et al. / Biochimica et Biophysica Acta 1842 (2014) 208–219transports hydrogen ions across the mitochondrial membrane and
disrupts ATP synthesis associated with Complex V activity. The third
compound is a combination of Rotenone, a Complex I inhibitor, plus
Antimycin A, a Complex III inhibitor, which together shut down mito-
chondrial respiration.
Most studies have focused on European mtDNA haplogroups. To
date there are very few cybrid model studies using the L haplogroups,
which are individuals with African maternal origins. In our study, the
L cybrids have similar levels of lactate and ATP production, suggesting
similar glycolysis and OXPHOS levels as compared to the European H
cybrids. We were surprised to ﬁnd that ROS levels in the L cybrids
were signiﬁcantly less than the H cybrids, because usually the ATPproduction and ROS levels parallel each other, as was seen when H
cybrids were compared to J cybrids [30]. Our ﬁndings suggest that in
the L haplogroupvariants, theremaynot be a direct correlation between
ROS production and mtDNA gene expression within the respiratory
complexes I and III. One possible explanation for the dissimilarity
between the ATP and ROS levels in L cybrids maybe that the L mtDNA
haplogroups are more efﬁcient in OXPHOS so electron leakage is
lower, resulting in diminished ROS formation.
Our Q-PCR studies demonstrate that although the L cybrids have
lower mtDNA copy numbers, they show higher expression levels for
nine of themtDNA-encoded respiratory complex genes,which are asso-
ciated with complexes I, III, IV and V, which suggests that these
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Fig. 4. The upper panel is a schematic of the current paradigm inwhich nuclear genes dominate cellular functions. The lower panel is a schematic which describes a new paradigm, based
upon our results with the model of cybrids, which have identical nuclei but differ in the mtDNA haplogroups (H versus L). We propose that mtDNA, which mediates energy production
pathways and ROS formation, can also greatly inﬂuence the expression of nuclear genes related to complement activation, inﬂammation and signaling pathways. As a result, the cells with
different mtDNA haplogroups (e.g., European versus African) will have different baseline expressions of major functional pathways. Therefore, since the cells will have unique comple-
ment/inﬂammation backgrounds, then responses of these cells to identical nuclear genes or environmental factors may then contribute to differential susceptibilities to diseases for
the different ethnic/racial haplogroups.
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trast, while mtRNA expression for L cybrids was 1.57-fold to 2.11-fold
higher than H cybrids, the cybrids that contained J haplogroup mtDNA
showed high levels of glycolysis and also signiﬁcantly lower expression
for the mtDNA-encoded OXPHOS genes (data not shown). Our data
demonstrate that themtDNA haplogroup variants can greatly inﬂuence
the efﬁciency of respiration, irrespective the nuclei, since in our cybrid
system all nuclei are identical.
The Seahorse Flux bioenergetic analyses showed that compared to
the European H cybrids, the L cybrids have lower ATP turnover and
lower spare respiratory capacity, which suggests that they may not be
able to respond to stress as readily as the H cybrids. The relationships
of elevated mtRNA expression levels but lower ATP turnover rates and
ROS production may be supportive of the theory that African mtDNA
variants are associated with endurance performance in elite athletes.
Scott and coworkers reported L0 haplogroups were found in higher
numbers of Kenyan athletes while L3 haplogroups were signiﬁcantly
reduced [31]. However, no correlation between haplogroups and athletic
performancewas found in Ethiopian athletes [32]. Further studieswill be
required to clarify in L cybrids the relationship between ATP production,
mtRNA expression levels and ROS production.
The H and L cybrids were similar to each other in their growth rates
patterns and lactate levels, but both cybrids differ considerably from the
European J cybrids, which showed preference toward use of glycolysis
and very rapid growth rates [30]. In summary, although H and L cybrids
had identical nuclei, the bioenergetic parameters and ROS levels were
different, reﬂecting the inﬂuence of the mtDNA on the cybrid “nuclear
machinery”. The mechanisms of nuclear–mitochondrial interactions in
mammalian cells are not understood but deserve much closer scrutiny.4.2. Differences in gene expression patterns identiﬁed by Affymetrix
GeneChip Array
Individuals with African background are at a higher risk for develop-
ing asthma and other inﬂammation-related diseases. The IPA summary
of the GeneChip array data (Table 3) showed that the H and L cybrids
possess differences in the pathways related to Complement System
and the CCR3 Signaling in Eosinophils. The CCR3 pathway is important
in neovascularization and inﬂammation, with the CCR3 receptor (also
known as eotaxin receptor) being expressed on eosinophils, airway
epithelial cells, basophils, mast cells and T2 helper cells [71]. The CCR3
receptors can be found in the human choroidal neovascular membrane
and various cancers [72–74]. In a mouse model, when CCR3 is blocked
then choroidal neovascularization is decreased [75]. Investigators sug-
gest that CCR3 plays a signiﬁcant role in the development of neovascu-
larization by promoting endothelial cell migration and activation of
VEGFR2 [76] andmay be a target for therapeutic intervention [77]. In ei-
ther case, the ﬁnding that expression of genes in the CCR3 pathway is
signiﬁcantly different between the H and L cybrids is notable because
the cybrids had identical nuclei but differed only in the mtDNA
haplogroups, suggesting that themtDNA canmediate thismajor inﬂam-
matory pathway.
The IPA program also identiﬁed ﬁve genes (CHST2, CHST5, SULT1C2,
HS3ST1 and CHST15) associated with the late stages of the Dermatan
sulfate (DS) and Chondroitin sulfate (CS) pathways as being signiﬁcantly
different between the H cybrids and L cybrids. All ﬁve enzymes are
sulfotransferases, which catalyze the transfer of sulfate onto DS, CS or
keratan sulfate (KS). This may be signiﬁcant for cellular behavior
because the degree of sulfation of GAGs canmediate biological functions
217M.C. Kenney et al. / Biochimica et Biophysica Acta 1842 (2014) 208–219[33], which include cellular proliferation, migration, differentiation,
angiogenesis and activation of cytokine/growth factors.
Studies show that DS and CS play a role in autoimmune diseases as
they can be targets for auto-antigen formation and responses of speciﬁc
auto-reactive B-1a cells [34]. For example, in SLE patients, CS can cross-
react with anti-DNA antibodies and in autoimmune thyroid disease and
diabetes, the urinary DS and CS levels correlate with disease severity
[35]. In patients with SLE and kidney disease, the ratio of chondroitin
sulfate to heparan sulfate can be used to identify the degree of disease
activity [36]. Campo and coworkers showed that chondroitin 4-sulfate
(C4S) have antioxidant properties by inhibiting lipid peroxidation and
lowering ROS damage, and suggested that GAGs can act as immuno-
modulators [37]. As part of the extracellular matrix (ECM) network,
the CS proteoglycans can inﬂuence the functions of immune cells during
pathologic central nervous system diseases [38]. At amolecular level, CS
may have antioxidant and anti-inﬂammatory properties because it can
decrease activation of NFκB, which in turn leads to lower expression
of pro-inﬂammatory cytokines [39–41].
A recent study showed that mutations in genes for biosynthetic
enzymes that sulfate CS and DS are associated with various connective
tissue diseases [42], which indicates that the sulfation patterns of
GAGs are very important for cellular behavior. Our ﬁndings demon-
strate that the expression ofﬁve sulfotransferase enzymes in the cybrids
are different based solely upon the mtDNA within the cell. Weiser and
coworkers have shown that auto-antibodies in SLE patients have selec-
tive binding to cell surface GAGs [43]. One can speculate that if there are
different levels of the negatively charged sulfates on DS and CS, such as
might be seen with the different expression levels of sulfotransferase
genes, this might inﬂuence the autoantibody-binding capacity to the
cells.
Finally, C1q inhibitor (C1q INH) is a chondroitin 4-sulfate proteogly-
can, which inhibits C1q activation by binding and precipitating the
molecule. C1q is critical for the ﬁrst steps of activation of the comple-
ment pathway, another pathway different in H cybrids compared to L
cybrids. This demonstrates a possible connection between the DS/CS
pathway and complement pathway, all of which are altered in the L
cybrids.
In summary, our GeneChip array data show that the mtDNA can
inﬂuence the expression levels for key sulfotransferase enzymes of
DS and CS, molecules which are involved with autoimmune diseases.
One can speculate that if the DS and CS have different sulfation pat-
terns, then cells may have different signaling and inﬂammation
pathways activated. This could lead to different susceptibilities of
European H haplogroup and African L haplogroup individuals to
high risk nuclear genes and/or environmental oxidative stressors.
Therefore, when examining the pathogenesis of diseases, we believe
it is important to evaluate the mtDNA background because some
mtDNA patterns may make a person more likely to get a disease
than other haplogroup patterns.
The mechanisms by which mtDNA can mediate the sulfotransferase
enzymes is unknown but deserves further studies. The mtDNA encodes
only 37 genes, no transcription factors and does not encode for any of
the genes that are altered in the Affymetrix Human U133 Plus 2.0
Array. Perhaps the ROS levels may inﬂuence the genes because the H
cybrids have higher ROS production than the L cybrids. It is less likely
that the ATP levels are involved since they have similar levels in the H
and L cybrids. Using the osteosacroma cybrid model, D'Aquila et al
reported that the SIRT3 gene contributes to the mitochondria–nuclear
cross talk after oxidative stress [78]. Furthermore, experiments with
Drosophila simulans which measured the catalytic capacity of the elec-
tron transport chain also showed the functional differences of mito-
chondrial metabolism were related to mtDNA haplogroups, and were
not mediated via mitochondrial–nuclear interactions or nuclear DNA
properties [79]. In any case, there is enough evidence accumulating
which supports a paradigm shift in thinking about mitochondrial–
nuclear interactions [80].4.3. Gene expression for complement pathway genes
The C1QC andC1R gene expressionswere signiﬁcantly lower in the L
cybrids compared to H cybrids. C1q binds with C1r and C1s to become
C1 complex of the classical pathway. As immunoglobulins bind to the
C1 complex, the proteases C1r and C1s are then activated, which
leads to further activation of the classical pathway. Complete genetic
deﬁciency of C1q is highly predictive of systemic lupus erythematosus
(SLE) disease and low C1q serum levels have been associated with
SLE ﬂare-ups [44]. Studies show that C1q has a regulatory role on
interferon-alpha, interleukin (IL)-6, IL-8 and tumor necrosis factor
(TNF)-alpha [45]. Deﬁciency of C1S is also associated with SLE-like syn-
dromes and glomerulonephritis [46]. These data indicate that mtDNA
variants can mediate gene expression for two components of the
classical pathway, which are important in inﬂammatory diseases.
Abnormalities of the alternative complement pathway are strongly
associatedwith various diseases and our cybridmodel shows signiﬁcant
effects of the haplogroups on that activity. The L cybrids have 0.58-fold
lower levels of the CFH inhibitor of complement compared to H cybrids
(p = 0.009). In a previous study, we reported that the J cybrids had sig-
niﬁcantly lower expression levels of two alternative pathway inhibitors,
CFH (0.5-fold lower, p = 0.0001) and CD55/DAF (0.6-fold lower,
p = 0.03) compared to the H cybrids [30]. Activation of the alternative
complement pathway and altered levels of CFH are linkedwith AD, obe-
sity and T2D [47–49]. If we extrapolate our cybrid ﬁndings to individ-
uals, then the H haplogroup subjects would have two inhibitors of the
alternative pathways (CFH and CD55), the L haplogroup subjects
would have decreased CFH inhibitor and J haplogroups would be deﬁ-
cient in two inhibitors. Then theoretically, the H individual would be
the most protected from complement activation, the L would be inter-
mediate and the J individuals would be highest risk. This scenario may
be amechanismbywhich ethnic/racial origins could inﬂuence develop-
ment of diseases which had major inﬂammation components.
Our ﬁndings thatmtDNAhaplogroupsmediate nuclear gene expres-
sion have been supported by others using the osteosarcoma cybrid
model, who reported the inﬂuence of mtDNA variants upon stress re-
sponse genes including heat shock protein (HSP)60, HSP75, IL-6, IL-1
and TNF-receptor2 [5,6]. In addition, cybrids from patients with
Huntington's disease and Leber hereditary optic neuropathy (LHON)
have shown that mtDNAmutations can affect various cellular functions
[50–53]. Therefore, our ﬁndings, along with cybrid studies using differ-
ent background Rho0 cells and different mtDNA, demonstrate that
mtDNA variants can affect nuclear gene expression of major molecular
pathways and cell behavior.
4.4. Inﬂammation pathway genes
IL-33 was identiﬁed by both GeneChip array and Q-PCR to be differ-
entially expressed in the L cybrids compared to H cybrids. This recently
discovered cytokine has generated tremendous interest because it plays
a key role in immune-inﬂammatory diseases and angiogenesis [54–56].
IL-33 seems to act as a “switch” cytokine which can alter expression of
IL-4, IL-5, IL-13, IgA, IgE and IgG levels [57–62] and also plays a role in
the induction of naive T cells to become cytokine-producing Th2 cells
[63–65]. In mice, IL-33 increases IgE serum levels and triggers degranu-
lation of mast cells [65].
IL-33 has a role in asthma, arthritis, cardiovascular disease, clearance
of parasites, central nervous system disease and various types of infec-
tions [66]. Milovanovic reports that the IL-33/ST2 complex plays a role
in animal models of diabetes, autoimmune diseases and cancer, and
that IL-33 can be anti-inﬂammatory for T cell responses [67]. Ali and
coworkers have shown that the full-length IL-33 interacts with NF-kB
by reducing its DNA binding capacity, which they suggest lowers gene
transcription and pro-inﬂammatory signaling [68]. If IL-33 acts as a
potent activator of the immune system, then differing levels could
greatly inﬂuence allergic and inﬂammatory responses. One can
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eases such as asthma and SLE in populations with maternal African ori-
gins. This is important because if cybrids with different mtDNA
haplogroups show disparity in the IL-33 expression levels, it may be a
mechanism by which innate immunity is involved in population sus-
ceptibilities of various diseases. In the future, IL-33 should be investigat-
ed as a potential trigger and therapeutic target site to diminish the
inﬂammatory component of human diseases.
The L cybrids have lower expression for TGF-alpha, a growth factor
with 40% homology to epidermal growth factor (EGF) that binds to
the EGF receptor, induces c-fos production and functions in cell
proliferation and differentiation [69,70]. TGF-alpha has been found in
retina, neural tissues and tumors [71–73]. Abnormal interactions
between TGF-alpha and the transcription factor IRF6 (interferon regula-
tory factor-6) are associated with tooth agenesis and cleft lip-palate
development [74]. Vieira has suggested that TGF-alpha is a geneticmod-
iﬁer associated with developmental diseases [75]. It has been suggested
that serum concentrations of TGF-alpha can be predictive for the
response to EGFR-tyrosine kinase inhibitors for the treatment of non-
small cell lung cancer [76]. TGF-alpha plays a role in the circadian
sleep–wake cycles and neuronal-retinal cell behavior through the
retinohypothalamic tract [77]. TGF-alpha is likely an important growth
factor that has a functional impact on diseases, and it is signiﬁcant
that expression levels vary based upon the mtDNA haplogroup.
Using both the GeneChip expression array and Q-PCR methods, we
found that the NFκB2 and MAPK10 gene expression levels for L cybrids
were higher than in H cybrids. Activation of NFκB2 has been associated
with inﬂammation and its inhibition has been linked to delayed growth
and apoptosis. MAPK10 (also known as JNK3) is responsible for
activating the Jun transcription factor and usually is distributed in
neurons, heart, testis and pancreatic islet cells [78,79]. MAPK10/JNK3
activation is elevated in human Alzheimer's disease and an AD mouse
model and JNK3 deletion improves cognition in familial AD mice [80].
In a retinal ganglion cell mouse model, JNK3 is involved with cell
death, which is a key feature of glaucoma [81]. Our ﬁndings are signiﬁ-
cant because we show that in cells with identical nuclei, changing
the mtDNA variants can lead to differential expression levels of NFκB2
and MAPK10/JNK3, important signaling molecules for many cellular
functions.
5. Conclusions
This study uses a cybrid model to study mitochondrial–nuclear
interactions and shows that although H and L cybrids have identical
nuclei, the bioenergetic parameters and ROS levels were distinctly
different from each other. In addition, Q-PCR analyses show differential
expression of genes associatedwith the cell signaling, complement acti-
vation, inﬂammation and innate immunity in the L cybrids compared to
H cybrids. Our ﬁndings demonstrate that mtDNA variants can mediate
nuclear gene expression and alter major functional pathways, which is
extremely important as different ethnic/racial populations have differ-
ent susceptibilities to diseases associated with complement activation
and inﬂammation. The cybrid model may offer insights into mecha-
nisms by which these disease susceptibilities may occur and help us to
identify novel targets for treatment.
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